Pfizer (PFE) : Fridays money flow data in Pfizer (PFE) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $47.96 million, whereas, $36.94 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.3, in favor of the bulls. The total money flow into the stock was $11.02 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $11.49 million. The total value of block trades done on upticks was $14.37 million. The value of bearish trades on downticks was only $2.89 million.The up/down ratio in the block trades was a healthy 4.98 in favor of the bulls, suggesting strong buying in the stock by large traders. Pfizer (PFE) fell $0.04 and traded at $34.65, down -0.1% for the day, over previous days close. On a weekly basis, the shares are -0.5% over the previous weeks close.
The company Insiders own 0.07% of Pfizer shares according to the proxy statements. Institutional Investors own 70.05% of Pfizer shares. During last six month period, the net percent change held by insiders has seen a change of -18.54%.
In a related news, The officer (Executive Vice President), of Pfizer Inc, Damelio Frank A had unloaded 100,000 shares at $34.49 per share in a transaction on May 26, 2016. The total value of transaction was $3,449,000. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Pfizer (NYSE:PFE): The stock opened at $34.78 and touched an intraday high of $34.84 on Friday. During the day, the stock corrected to an intraday low of $34.61, however, the bulls stepped in and pushed the price higher to close in the green at $34.77 with a gain of 0.26% for the day. The total traded volume for the day was 14,435,849. The stock had closed at $34.68 in the previous trading session.
Pfizer (PFE) : During the past 4 weeks, traders have been relatively bearish on Pfizer (PFE), hence the stock is down -1.76% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.64% relative to the S&P 500. The 4-week change in the price of the stock is -1.89% and the stock has fallen -0.14% in the past 1 week.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.